Correct. And all that ultimately adds up to safety, efficacy, very low production cost and easy administration of vaccine as well. So many advantages.
Meanwhile, with all these advantages and potentially better in-house combos, why are they bothering to trial those PD1vaxx/Tecentriq and Hervaxx/Keytruda combo trials? Maybe to get data to compare to those potential in-house combos to prove the Professor's point? And if proven, then bidding frenzy?
- Forums
- ASX - By Stock
- Ann: Science Series CHECKvacc
Correct. And all that ultimately adds up to safety, efficacy,...
-
- There are more pages in this discussion • 120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
Add IMU (ASX) to my watchlist
|
|||||
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 5.1¢ | $674.9K | 12.90M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 45087 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 519803 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 45087 | 0.052 |
11 | 671034 | 0.051 |
81 | 7658639 | 0.050 |
23 | 3483045 | 0.049 |
19 | 831259 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 384611 | 4 |
0.054 | 2188679 | 7 |
0.055 | 670630 | 7 |
0.056 | 1929043 | 11 |
0.057 | 1626859 | 12 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |